Internal Medicine, Endocrinology, Diabetes, & Metabolism · McKinney, TX
NPI
1194011999
Since 2011
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
4521 Medical Center Dr Ste 400
McKinney, TX, 75069
Phone (214) 547-7557
Groups this clinician bills Medicare through
Medicare paid, 2024
$281K
5,477 services
Medicare patients, 2024
762
Average age 74
Drug cost, 2024
$3.4M
5,715 prescriptions
Company payments, 2025
$30K
From 25 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Muhammad S Siddiqui was code 99490 (chronic, principal, and transitional care management), 1,362 times for 231 patients. In total Muhammad S Siddiqui billed 5,477 services in 22 codes, and Medicare paid $281K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-02-24.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99490 Chronic, Principal, and Transitional Care Management | Office | 1,362 | 231 | $48.23 | $66K |
| 99214 Office E&M - Established | Office | 1,198 | 612 | $88.73 | $106K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 889 | 533 | $12.13 | $11K |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 538 | 217 | $37.00 | $20K |
| 99426 Chronic, Principal, and Transitional Care Management | Office | 449 | 101 | $48.04 | $22K |
| 95251 Test - Miscellaneous | Office | 417 | 178 | $25.46 | $11K |
| 99232 Hospital E&M - Subsequent | Facility | 175 | 52 | $60.10 | $11K |
| 99427 Chronic, Principal, and Transitional Care Management | Office | 145 | 69 | $36.61 | $5,308 |
| 99204 Office E&M - New | Office | 112 | 112 | $120.25 | $13K |
| 99222 Hospital E&M - Initial | Facility | 64 | 59 | $99.37 | $6,360 |
| 99233 Hospital E&M - Subsequent | Facility | 44 | 25 | $90.40 | $3,977 |
| 99213 Office E&M - Established | Office | 26 | 25 | $62.21 | $1,617 |
| 99215 Office E&M - Established | Office | 17 | 13 | $115.48 | $1,963 |
| 99223 Hospital E&M - Initial | Facility | 12 | 11 | $122.84 | $1,474 |
By year: 2022 $141K for 1,755 services; 2023 $250K for 4,267 services; 2024 $281K for 5,477 services.
Medicare prescription drug claims, 2024
In 2024, the drug Muhammad S Siddiqui prescribed most often to Medicare patients was Levothyroxine Sodium, with 603 prescriptions and refills. In total Muhammad S Siddiqui wrote 5,715 Medicare prescriptions that cost $3.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 603 | 1,657 | 209 | $5,839 |
| Ozempic Semaglutide | 467 | 961 | 166 | $899K |
| Metformin Hcl Generic | 314 | 913 | 123 | $2,816 |
| Atorvastatin Calcium Generic | 239 | 667 | 90 | $1,955 |
| Tresiba Flextouch U-200 Insulin Degludec | 196 | 515 | 69 | $228K |
| Mounjaro Tirzepatide | 194 | 344 | 61 | $366K |
| Farxiga Dapagliflozin Propanediol | 177 | 421 | 58 | $228K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 161 | 447 | 81 | $17K |
| Glimepiride Generic | 149 | 407 | 55 | $1,380 |
| Jardiance Empagliflozin | 137 | 352 | 47 | $198K |
| Tresiba Flextouch U-100 Insulin Degludec | 131 | 376 | 57 | $82K |
| Metformin Hcl Er Metformin Hcl | 96 | 283 | 38 | $1,075 |
| Alendronate Sodium Generic | 90 | 250 | 36 | $1,268 |
| Liothyronine Sodium Generic | 87 | 242 | 31 | $3,380 |
| Methimazole Generic | 85 | 218 | 33 | $1,054 |
Brand drugs: 2,875 claims; generic drugs: 2,350 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Muhammad S Siddiqui $30K ($30K in general payments such as food, travel and fees) from 25 companies. The largest payer was Novo Nordisk Inc with $28K.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 44 | $28K |
| Amgen Inc. AMGN | 14 | $368 |
| Mannkind Corporation MNKD | 9 | $223 |
| Abbott Laboratories ABT | 10 | $194 |
| Sequel Med Tech, LLC | 4 | $176 |
| Xeris Pharmaceuticals, Inc. | 8 | $150 |
| Lilly USA, LLC LLY | 7 | $123 |
| Amneal Pharmaceuticals LLC AMRX | 5 | $108 |
| Radius Health, Inc. | 5 | $92.32 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 4 | $76.26 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.